Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab
- Monday, December 3, 2018, 1:01
- PR Newswire
- Add a comment
ZUG, Switzerland, December 3, 2018 /PRNewswire/ — Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today it has entered into a worldwide collaboration and license agreement with argenx BVBA and argenx SE, to develop and…
Source: https://www.prnewswire.com:443/news-releases/janssen-affiliate-cilag-gmbh-international-enters-worldwide-collaboration-and-license-agreement-with-argenx-for-cancer-immunotherapy-cusatuzumab-300758748.html
About the Author
admin has written 20720 stories on this site.